Ebb & Flow

The proposed deal to rid Wall Street of research-related conflicts of interest could be a boon for the firms that weren't a party to the settlement, at least temporarily, and offer biotech some hope that it will not be knocked off the radar by the new economics of equity research coverage.

But the SEC told Ebb & Flow that the deal should be viewed as the shape of things to come on the regulatory front, which would give banks not included in the settlement only a short term advantage...